tetano
Editor, Senior Moderator
Sci Rep. 2016 Jul 6;6:29154. doi: 10.1038/srep29154.
[h=1]Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection.[/h] Stevens NE[SUP]1[/SUP], Hatjopolous A[SUP]1[/SUP], Fraser CK[SUP]2[/SUP], Alsharifi M[SUP]3[/SUP], Diener KR[SUP]1,[/SUP][SUP]4[/SUP], Hayball JD[SUP]1,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Passive immunotherapy may have particular benefits for the treatment of severe influenza infection in at-risk populations, however little is known of the impact of passive immunotherapy on the formation of memory responses to the virus. Ideally, passive immunotherapy should attenuate the severity of infection while still allowing the formation of adaptive responses to confer protection from future exposure. In this study, we sought to determine if administration of influenza-specific ovine polyclonal antibodies could inhibit adaptive immune responses in a murine model of lethal influenza infection. Ovine polyclonal antibodies generated against recombinant PR8 (H1N1) hemagglutinin exhibited potent prophylactic capacity and reduced lethality in an established influenza infection, particularly when administered intranasally. Surviving mice were also protected against reinfection and generated normal antibody and cytotoxic T lymphocyte responses to the virus. The longevity of ovine polyclonal antibodies was explored with a half-life of over two weeks following a single antibody administration. These findings support the development of an ovine passive polyclonal antibody therapy for treatment of severe influenza infection which does not affect the formation of subsequent acquired immunity to the virus.
PMID: 27380890 DOI: 10.1038/srep29154
[PubMed - as supplied by publisher]
[h=1]Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection.[/h] Stevens NE[SUP]1[/SUP], Hatjopolous A[SUP]1[/SUP], Fraser CK[SUP]2[/SUP], Alsharifi M[SUP]3[/SUP], Diener KR[SUP]1,[/SUP][SUP]4[/SUP], Hayball JD[SUP]1,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Passive immunotherapy may have particular benefits for the treatment of severe influenza infection in at-risk populations, however little is known of the impact of passive immunotherapy on the formation of memory responses to the virus. Ideally, passive immunotherapy should attenuate the severity of infection while still allowing the formation of adaptive responses to confer protection from future exposure. In this study, we sought to determine if administration of influenza-specific ovine polyclonal antibodies could inhibit adaptive immune responses in a murine model of lethal influenza infection. Ovine polyclonal antibodies generated against recombinant PR8 (H1N1) hemagglutinin exhibited potent prophylactic capacity and reduced lethality in an established influenza infection, particularly when administered intranasally. Surviving mice were also protected against reinfection and generated normal antibody and cytotoxic T lymphocyte responses to the virus. The longevity of ovine polyclonal antibodies was explored with a half-life of over two weeks following a single antibody administration. These findings support the development of an ovine passive polyclonal antibody therapy for treatment of severe influenza infection which does not affect the formation of subsequent acquired immunity to the virus.
PMID: 27380890 DOI: 10.1038/srep29154
[PubMed - as supplied by publisher]